{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-21-015672","form_type":"8-K","ticker":"OKUR","cik":"0001637715","company_name":"OnKure Therapeutics, Inc.","filed_at":"2021-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.427417+00:00","generated_at":"2026-06-28T09:15:06.447705+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Reneo Pharma Q3 2021 net loss $12.7M; cash $157.7M; trial progress","bullets":["Net loss of $12.7M ($0.52/share) vs $5.1M ($2.48/share) in Q3 2020.","Cash, equivalents and short-term investments $157.7M as of Sept 30, 2021.","Initiated STRIDE Phase 2b trial for REN001 in PMM; completed LC-FAOD Phase 1b enrollment.","Appointed Ashley Hall as Chief Development Officer; received US patent notice of allowance for REN001 into 2041.","Expects Phase 1b results for McArdle disease Q1 2022 and LC-FAOD Q2 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-21-015672","json":"https://secwatch.observer/filing/0001558370-21-015672.json","markdown":"https://secwatch.observer/filing/0001558370-21-015672.md","text":"https://secwatch.observer/filing/0001558370-21-015672.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1637715/000155837021015672/0001558370-21-015672-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1637715/000155837021015672/rphm-20211111x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T09:15:06.447705+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}